<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2050">
  <stage>Registered</stage>
  <submitdate>15/07/2008</submitdate>
  <approvaldate>15/07/2008</approvaldate>
  <nctid>NCT00716976</nctid>
  <trial_identification>
    <studytitle>Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy</studytitle>
    <scientifictitle>A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>COG-ACCL0431</secondaryid>
    <secondaryid>ACCL0431</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain Tumor</healthcondition>
    <healthcondition>Central Nervous System Tumor</healthcondition>
    <healthcondition>Childhood Germ Cell Tumor</healthcondition>
    <healthcondition>Extragonadal Germ Cell Tumor</healthcondition>
    <healthcondition>Liver Cancer</healthcondition>
    <healthcondition>Neuroblastoma</healthcondition>
    <healthcondition>Ototoxicity</healthcondition>
    <healthcondition>Ovarian Cancer</healthcondition>
    <healthcondition>Sarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Other</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Testicular</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - sodium thiosulfate
Treatment: surgery - examination

Experimental: STS Arm (sodium thiosulfate treatment) - Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.

Experimental: Observation Arm (No sodium thiosulfate treatment) - Patients do not receive sodium thiosulfate.


Treatment: drugs: sodium thiosulfate
Given IV

Treatment: surgery: examination
Patients undergo audiological assessments periodically

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Hearing Loss - Hearing loss defined by comparing hearing sensitivity at follow up evaluation relative to baseline measurements using ASHA criteria.</outcome>
      <timepoint>4 weeks after last dose of cisplatin</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Hearing Thresholds For Key Frequencies at 500 hz - Mean change in hearing threshold (post-pre) at 500 hz.</outcome>
      <timepoint>4 weeks after last dose of cisplatin</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Hearing Thresholds For Key Frequencies at 1000 hz - Mean change in hearing threshold (post-pre) at 1000 hz.</outcome>
      <timepoint>4 weeks after last dose of cisplatin</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Hearing Thresholds For Key Frequencies at 2000 hz - Mean change in hearing threshold (post-pre) at 2000 hz</outcome>
      <timepoint>4 weeks after last dose of cisplatin</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Hearing Thresholds For Key Frequencies at 4000 hz - Mean change in hearing threshold (post-pre) at 4000 hz.</outcome>
      <timepoint>4 weeks after last dose of cisplatin</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Hearing Thresholds For Key Frequencies at 8000 hz - Mean change in hearing threshold (post-pre) at 8000 hz.</outcome>
      <timepoint>4 weeks after last dose of cisplatin</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event-Free Survival (EFS) - Proportion of patients event free at 4 years following enrollment. See EFS outcome measure description.</outcome>
      <timepoint>4 years after enrollment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - Proportion of patients alive free at 4 years following enrollment. See OS outcome measure description.</outcome>
      <timepoint>4 Years after enrollment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT)</outcome>
      <timepoint>4 weeks after the last dose of cisplatin</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Newly diagnosed (previously untreated or currently receiving cancer treatment for the
             diagnosis that made the patient eligible for this study) with germ cell tumor,
             hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy

          -  Planning to receive a chemotherapy treatment regimen that includes a cumulative
             cisplatin dose = 200 mg/m² with individual cisplatin doses to be infused over = 6
             hours

          -  Enrolled on hearing assessment clinical trial COG-ACCL05C1

               -  Normal auditory results

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status (PS) 50-100% (for patients &gt; 16 years of age)

          -  Lansky PS 50-100% (for patients = 16 years of age)

          -  Serum sodium normal

          -  Absolute granulocyte count &gt; 1,000/mm³

          -  Platelet count &gt; 100,000/mm³

          -  Creatinine clearance or radioisotope glomerular filtration rate = 70mL/min OR serum
             creatinine between 0.4 and 1.7 mg/dL, based on age and gender

          -  Total bilirubin = 1.5 times upper limit of normal (ULN) for age

          -  AST or ALT &lt; 2.5 times ULN for age

          -  Not pregnant or nursing

          -  Negative pregnancy test (if patient has child-bearing capacity)

          -  Fertile patients must use effective contraception

          -  No known hypersensitivity to sodium thiosulfate or other thiol agents (e.g.,
             amifostine trihydrate, N-acetylcysteine, MESNA, or captopril)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior platinum-based chemotherapy (cisplatin or carboplatin)

               -  Other prior chemotherapy allowed

          -  Prior cranial radiotherapy (e.g., for treatment of medulloblastoma) allowed provided
             normal hearing is documented after completion of radiotherapy and before enrollment
             and administration of cisplatin chemotherapy

          -  At least 6 months since prior hematopoietic stem cell transplantation.

               -  No evidence of graft-versus-host disease

          -  No concurrent enrollment on another COG clinical trial for treatment of the cancer.

               -  Concurrent enrollment on a non-COG clinical trial (e.g., Head start) allowed.

          -  Cranial irradiation after the completion of all systemic chemotherapy allowed provided
             post end-of-treatment audiometry is completed prior to beginning irradiation.

          -  Concurrent radiotherapy to extracranial sites allowed.</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Supportive Care</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>131</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving
      cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than
      no additional treatment in preventing hearing loss.

      PURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it
      works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed
      germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other
      malignancy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00716976</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David R. Freyer, DO, MS</name>
      <address>Children's Hospital Los Angeles</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>